Total Payments
$1,888
2024 Payments
$717.38
Companies
40
Transactions
72
Medicare Patients
2,713
Medicare Billing
$405,534
Payment Breakdown by Category
Food & Beverage$1,722 (91.2%)
Other$150.00 (7.9%)
Education$16.48 (0.9%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $1,722 | 70 | 91.2% |
| Honoraria | $150.00 | 1 | 7.9% |
| Education | $16.48 | 1 | 0.9% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Janssen Biotech, Inc. | $162.65 | 4 | $0 (2022) |
| Athenex Pharmaceutical Division, LLC | $150.00 | 1 | $0 (2020) |
| Novartis Pharmaceuticals Corporation | $138.44 | 7 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $124.56 | 3 | $0 (2024) |
| Covidien LP | $116.00 | 1 | $0 (2019) |
| Amgen Inc. | $105.17 | 6 | $0 (2020) |
| Intera Oncology, Inc | $68.70 | 1 | $0 (2024) |
| Incyte Corporation | $67.51 | 3 | $0 (2024) |
| Merck Sharp & Dohme Corporation | $53.39 | 3 | $0 (2019) |
| Celgene Corporation | $53.17 | 3 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $717.38 | 29 | Intera Oncology, Inc ($68.70) |
| 2023 | $40.10 | 2 | Alnylam Pharmaceuticals Inc. ($20.67) |
| 2022 | $123.76 | 1 | Janssen Biotech, Inc. ($123.76) |
| 2020 | $235.61 | 6 | Athenex Pharmaceutical Division, LLC ($150.00) |
| 2019 | $648.09 | 30 | Covidien LP ($116.00) |
| 2017 | $123.49 | 4 | E.R. Squibb & Sons, L.L.C. ($99.96) |
All Payment Transactions
72 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | Karyopharm Therapeutics Inc. | XPOVIO (Drug) | Food and Beverage | In-kind items and services | $16.54 | General |
| Category: Oncology | ||||||
| 12/16/2024 | Fennec Pharmaceuticals, Inc. | Pedmark (Drug) | Food and Beverage | In-kind items and services | $23.34 | General |
| Category: Cisplatin-induced Ototoxicity | ||||||
| 12/13/2024 | ADC Therapeutics America, Inc. | — | Food and Beverage | In-kind items and services | $36.21 | General |
| 12/11/2024 | Astellas Pharma US Inc | Xtandi (Drug) | Food and Beverage | In-kind items and services | $17.87 | General |
| Category: Oncology | ||||||
| 12/09/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $14.52 | General |
| Category: Oncology | ||||||
| 12/04/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $26.21 | General |
| Category: ONCOLOGY | ||||||
| 11/27/2024 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Food and Beverage | Cash or cash equivalent | $47.28 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 11/22/2024 | Astellas Pharma US Inc | Xtandi (Drug) | Food and Beverage | In-kind items and services | $16.78 | General |
| Category: Oncology | ||||||
| 11/21/2024 | TAIHO ONCOLOGY, INC. | LONSURF (Drug), INQOVI | Food and Beverage | In-kind items and services | $15.14 | General |
| Category: Oncology | ||||||
| 11/13/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $20.24 | General |
| Category: Rare Disease | ||||||
| 11/12/2024 | Blueprint Medicines Corporation | AYVAKIT (Drug) | Food and Beverage | In-kind items and services | $29.68 | General |
| Category: Oncology / Rare Diseases | ||||||
| 11/12/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $24.60 | General |
| Category: Oncology | ||||||
| 11/11/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $27.06 | General |
| Category: ONCOLOGY | ||||||
| 11/07/2024 | SpringWorks Therapeutics, Inc. | OGSIVEO (Drug) | Food and Beverage | In-kind items and services | $22.05 | General |
| Category: DESMOID TUMORS | ||||||
| 11/06/2024 | ABBVIE INC. | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $34.26 | General |
| Category: ONCOLOGY | ||||||
| 11/06/2024 | Acrotech Biopharma Inc. | BELEODAQ (Drug) | Food and Beverage | In-kind items and services | $14.86 | General |
| Category: ONCOLOGY | ||||||
| 11/05/2024 | Incyte Corporation | PEMAZYRE (Drug), MONJUVI | Food and Beverage | Cash or cash equivalent | $20.78 | General |
| Category: Hepatology (Liver, Pancreatic, Gall Bladder) | ||||||
| 11/03/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $13.07 | General |
| Category: Oncology | ||||||
| 10/31/2024 | Fennec Pharmaceuticals, Inc. | Pedmark (Drug) | Food and Beverage | In-kind items and services | $11.76 | General |
| Category: Cisplatin-induced Ototoxicity | ||||||
| 10/30/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $22.65 | General |
| 10/30/2024 | SOBI, INC | VONJO (Drug) | Food and Beverage | In-kind items and services | $15.61 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 10/29/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $32.47 | General |
| Category: ONCOLOGY | ||||||
| 10/29/2024 | Incyte Corporation | MONJUVI (Drug), PEMAZYRE | Food and Beverage | Cash or cash equivalent | $28.09 | General |
| Category: Oncology | ||||||
| 10/22/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $18.12 | General |
| Category: Oncology | ||||||
| 10/22/2024 | Fennec Pharmaceuticals, Inc. | Pedmark (Drug) | Food and Beverage | In-kind items and services | $14.18 | General |
| Category: Cisplatin-induced Ototoxicity | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 290 | 422 | $58,435 | $12,425 |
| 2022 | 11 | 837 | 1,784 | $451,984 | $145,053 |
| 2021 | 11 | 988 | 2,002 | $486,457 | $163,117 |
| 2020 | 10 | 598 | 1,048 | $301,100 | $84,938 |
Total Patients
2,713
Total Services
5,256
Medicare Billing
$405,534
Procedure Codes
37
All Medicare Procedures & Services
37 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 44 | 44 | $33,000 | $6,175 | 18.7% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 40 | 51 | $13,770 | $3,380 | 24.5% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 94 | 151 | $6,342 | $1,563 | 24.6% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 99 | 157 | $4,867 | $1,195 | 24.5% |
| 83615 | Lactate dehydrogenase (enzyme) level | Office | 2023 | 13 | 19 | $456.00 | $112.48 | 24.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 302 | 902 | $257,070 | $84,567 | 32.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 55 | 194 | $74,302 | $29,193 | 39.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 55 | 55 | $23,925 | $7,366 | 30.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 76 | 85 | $16,575 | $5,301 | 32.0% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 33 | 35 | $26,250 | $5,216 | 19.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 22 | 22 | $12,034 | $3,969 | 33.0% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 30 | 53 | $14,310 | $3,039 | 21.2% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 16 | 34 | $13,090 | $2,818 | 21.5% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2022 | 112 | 189 | $7,938 | $1,975 | 24.9% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2022 | 112 | 190 | $5,890 | $1,460 | 24.8% |
| 83615 | Lactate dehydrogenase (enzyme) level | Office | 2022 | 24 | 25 | $600.00 | $149.26 | 24.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 367 | 1,135 | $323,475 | $116,817 | 36.1% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 81 | 81 | $44,307 | $14,265 | 32.2% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 64 | 64 | $27,840 | $7,767 | 27.9% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 89 | 107 | $20,865 | $7,471 | 35.8% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 31 | 35 | $26,250 | $5,701 | 21.7% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 27 | 43 | $11,610 | $2,607 | 22.5% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2021 | 138 | 236 | $9,912 | $2,492 | 25.1% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 12 | 23 | $8,855 | $2,001 | 22.6% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 12 | 14 | $5,362 | $1,995 | 37.2% |
About Dr. Venkata Parsa, MD
Dr. Venkata Parsa, MD is a Medical Oncology healthcare provider based in Fort Myers, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/22/2007. The National Provider Identifier (NPI) number assigned to this provider is 1518156959.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Venkata Parsa, MD has received a total of $1,888 in payments from pharmaceutical and medical device companies, with $717.38 received in 2024. These payments were reported across 72 transactions from 40 companies. The most common payment nature is "Food and Beverage" ($1,722).
As a Medicare-enrolled provider, Parsa has provided services to 2,713 Medicare beneficiaries, totaling 5,256 services with total Medicare billing of $405,534. Data is available for 4 years (2020–2023), covering 37 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Location Fort Myers, FL
- Active Since 10/22/2007
- Last Updated 04/16/2025
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1518156959
Products in Payments
- Oral Paclitaxel (Drug) $150.00
- ERLEADA (Drug) $123.76
- superDimension (Device) $116.00
- INTERA (Device) $68.70
- PROMACTA (Drug) $63.38
- ELIQUIS (Drug) $50.61
- PROVENGE (Drug) $49.57
- ORENCIA (Biological) $49.35
- Pedmark (Drug) $49.28
- FOUNDATIONONE (Device) $47.71
- Rezlidhia (Drug) $47.28
- IMBRUVICA (Drug) $47.13
- Lenvima (Drug) $46.99
- Abraxane (Drug) $41.19
- KISQALI (Drug) $40.46
- Xtandi (Drug) $34.65
- VOTRIENT (Drug) $34.60
- LYNPARZA (Biological) $34.54
- FRUZAQLA (Drug) $34.09
- Kyprolis (Biological) $32.88
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Medical Oncology Doctors in Fort Myers
Dr. Lowell Hart, M.d, M.D
Medical Oncology — Payments: $402,512
Medical Oncology $402,512
Dr. James Reeves, M.d, M.D
Medical Oncology — Payments: $198,428
Medical Oncology $198,428
Dr. Michael Mccleod, Do, DO
Medical Oncology — Payments: $63,904
Medical Oncology $63,904
Dr. Vitor Pastorini Filho, M.d, M.D
Medical Oncology — Payments: $18,036
Medical Oncology $18,036
Dr. Van Rana, 09221980, 09221980
Medical Oncology — Payments: $9,740
Medical Oncology $9,740
Dr. Manoel Moraes, Md, MD
Medical Oncology — Payments: $1,670
Medical Oncology $1,670